Researchers Developed Light-Sensitive Retinal Nanoparticles
The team created non-surgical nanoparticles to trigger nerve cell activation, a process validated in rodent models.
Updated on Sept. 24, 2026 in Materials Science
Live Poll
Do you believe prioritizing non-surgical medical breakthroughs is the best approach for treating vision loss?
In research initiated in 2019, scientists developed 300-nanometer light-sensitive particles to enable non-surgical retinal stimulation. The team demonstrated visual cortex activity in mice models suffering from retinitis pigmentosa.
Why it matters
This research provides a potential alternative to existing treatment options that currently require invasive surgery or specific genetic modifications to restore retinal function. The project aims to simplify the therapeutic process by leveraging light-responsive materials.
The nanoparticles are constructed from graphitic carbon nitride and measure 300 nanometers in diameter. Their performance is measured by their ability to trigger nerve cell activation in the visual cortex of mice.
The players
Aarhus University
A Danish research institution that led the development of the light-sensitive nanoparticles.
RetinaNano
A research project focused on non-surgical retinal stimulation that secured a 2025 Pioneer Innovator grant.
The details
The process involves injecting the nanoparticles into the eye, where they settle adjacent to retinal ganglion cells—neurons located near the inner surface of the retina that relay visual information to the brain. Upon exposure to light, these particles initiate electrical and chemical processes that activate the nerve cells. This mechanism circumvents the need for traditional surgical intervention or complex genetic engineering, which are currently required for other retinal stimulation therapies.
Timeline
The research project began in 2019.
The team filed an international patent application in 2024.
The RetinaNano project received a Pioneer Innovator grant in 2025.
The Tech Race
The development of these nanoparticles marks a shift from invasive electronic retinal prosthetics toward minimally invasive chemical-material solutions. This trajectory competes with existing surgical standards by aiming to simplify the interface between external light and neural activation.
The technology is currently in the research phase and is not yet available for clinical use. Future applications will depend on successful longitudinal human safety trials to confirm the material's stability within the eye.
The takeaway
This research highlights a transition toward biological-material interfaces that bypass the need for surgical hardware. Future progress can be tracked through upcoming long-term safety studies and the evolution of the 2024 international patent application.
Further reading
For more on the development of light-responsive materials, see Materials Science.
Source note: This article includes information reported by Jordan News | Latest News from Jordan, MENA.
Live Poll
Do you believe prioritizing non-surgical medical breakthroughs is the best approach for treating vision loss?
